Abstract: FR-PO0219
Therapeutic Potential of Muscle Strengthening to Improve Anemia and Reduce Soluble Fas in Patients on Hemodiafiltration
Session Information
- Anemia and Iron Metabolism
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Authors
- Andrade, Jessica Liara Felicio de, Universidade Federal de Sao Paulo Escola Paulista de Medicina, São Paulo, Brazil
- Rodrigues, Adelson, Universidade Federal de Sao Paulo Escola Paulista de Medicina, São Paulo, Brazil
- Viana, Victória, Universidade Federal de Sao Paulo Escola Paulista de Medicina, São Paulo, Brazil
- Faria de Oliveira, Mayron, Physiotherapy Unit, VO2 Care, São Paulo, Brazil
- Goes, Miguel Angelo, Universidade Federal de Sao Paulo Escola Paulista de Medicina, São Paulo, Brazil
Background
End Stage Kidney Disease (ESKD) is a significant global public health concern, frequently accompanied by systemic complications, most notably anemia. ESKD may worse by anemia. Elevated soluble Fas levels (sFas) have been linked to impaired erythropoiesis and reduced responsiveness to erythropoietin (EPO). In this context, muscle strengthening has gained attention to mitigate complications and improve clinical outcomes in ESKD. OBJECTIVE: To evaluate the effects of muscle strengthening on anemia and soluble Fas levels in hemodiafiltration (HDF) patients.
Methods
We initially conducted a retrospective study with 38 patients undergoing dialysis, comparing patients who only underwent HDF (HDF+SD; sedentary group; n=11) with those who had muscle strengthening(MS) performed during dialysis (HDF+MS;n=27). EPO, sFas, and complete blood count parameters were assessed at baseline and after 12 weeks. Paired Student’s t-tests were applied, with significance set at p<0.05.
Results
21 patients were male. The main etiology of ESKD was diabetes mellitus, followed by hypertension and glomerulopathies. After 12 weeks, EPO levels decreased in HDF+SD (6.55±0.05 mIU/mL vs. 5.84±0.81 mIU/mL; p=0.02) but remained stable in the HDF+MS (6.59±0.09 mIU/mL vs 6.79±3.08 mIU/mL; p=0.77). During the same period, sFas levels declined in HDF+SD (796±87.3 pg/mL vs. 430±23.3; pg/mL; p=0.22) whereas a significant reduction was observed in HDF+MS (517±31.2; pg/mL vs. 321±3.1 pg/mL; p=0.04). Hemoglobin levels showed no significant change in HDF+SD while a significant increase was found in HDF+MS (11.4±0.8 g/dL vs. 12.2±0.9 g/dL; p=0.002).
Conclusion
In conclusion, the results demonstrated that, at 12 weeks, patients undergoing HDF+MS presented preservation of serum EPO and reduction in Fas values. In addition, there was a higher Hb concentration with the same dosage of the erythropoiesis-stimulating agent. The integration of structured exercise into dialysis treatment may offer a feasible and impactful intervention to improve clinical outcomes and quality of life in patients with CKD.
Funding
- Government Support – Non-U.S.